Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-FZ-NR-1
- Development stage
- Unknown
- Lead developer
- Fudan University Shanghai Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Cyclic Peptides → Modified Peptides → Peptides
- Administration
- Intravenous
01
Overview
177Lu-FZ-NR-1 is a nectin-4-targeted radiopharmaceutical consisting of a bicyclic peptide (FZ-NR-1) labeled with the beta-emitting radionuclide lutetium-177. It is designed for the targeted radiotherapy of tumors overexpressing Nectin-4, such as urothelial carcinoma and triple-negative breast cancer. In preclinical studies, it serves as a non-covalent reference compound compared against newer covalent-binding radioligands (covalent 177Lu-FZ-NRs) developed using a SuFEx-bio-orthogonal strategy. The drug works by binding to Nectin-4 on the surface of cancer cells, allowing for the localized delivery of ionizing radiation to induce DNA damage and cell death. It was developed by researchers at Fudan University Shanghai Cancer Center.
- Other names
- 177Lu-labeled Nectin-4-targeted bicyclic peptidenon-covalent 177Lu-FZ-NR-1non-covalent177Lu-FZ-NR-1non-covalent-177Lu-FZ-NR-1
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on 177Lu-FZ-NR-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-FZ-NR-1.